Key Drivers
- Stable margins
- High leverage
- Weak earnings
AIAI Summary
TFX is no longer just a steady medtech compounder; it is now a margin-repair and strategic-optionality story where upside depends on management proving it can convert stable revenue and cash flow into durable earnings before leverage, integration drag, and legal overhangs keep the stock capped.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Stable margins
- •High leverage
- •Weak earnings
TFX shows stable gross margins and decent liquidity with positive operating cash flow, but high leverage, weak interest coverage, and continued net losses keep the core earnings profile fragile.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Resistance overhead
- •Rebound intact
Over the last month, TFX looks neutral to slightly constructive, holding above the $129-$130 support after a sharp selloff but still capped by $133-$139 resistance.
Sharp drop from $138.81 to $119.89, followed by a quick rebound
Sentiment & News
Key News Insights:
- •Revenue Growth
- •Margin Pressure
- •Takeover Speculation
Teleflex delivered strong Q1 revenue growth and an adjusted EPS beat, but weaker margins, a CEO transition, legal scrutiny, and take-private speculation kept the stock under pressure.
The mix of improved sales and weaker profitability suggests limited near-term upside as investors weigh leadership change, legal risk, and acquisition chatter
Similar Companies in Healthcare
Other companies in the same sector with AI ratings